ArticleISRN gastroenterology2012
Helicobacter pylori Eradication Therapy: Current Availabilities.
Article in ISRN gastroenterology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a prospective randomized study.European journal of clinical pharmacology · 2013Trial
- Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study.BMC gastroenterology · 2013Trial
- Two-week triple therapy has a higher Helicobacter pylori eradication rate than 1-week therapy: A single-center randomized study.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationTrial
- Analysis of Helicobacter pylori resistance in patients with different gastric diseases.Scientific reports · 2024Article
- Novel Mutations Conferring Amoxicillin Resistance inAntibiotics (Basel, Switzerland) · 2023Article
- Combating multidrug-resistant Helicobacter pylori with moenomycin A in combination with clarithromycin or metronidazole.Frontiers in chemistry · 2022Article
- Article
- Can Aminoglycosides Be Used as a New Treatment forInfection & chemotherapy · 2019Article
- Review
- Antiulcer Activity and Potential Mechanism of Action of the Leaves ofOxidative medicine and cellular longevity · 2018Article
- High antibiotic resistance rate: A difficult issue for Helicobacter pylori eradication treatment.World journal of gastroenterology · 2015Review
- Antibiotic treatment for Helicobacter pylori: Is the end coming?World journal of gastrointestinal pharmacology and therapeutics · 2015Review
- Mechanisms of gastroprotection of methanol extract of Melastoma malabathricum leaves.BMC complementary and alternative medicine · 2015Article
- Choosing optimal first-line Helicobacter pylori therapy: a view from a region with high rates of antibiotic resistance.Current pharmaceutical design · 2014Review
- Increasing gastric juice pH level prior to anti-Helicobacter pylori therapy may be beneficial to the healing of duodenal ulcers.Experimental and therapeutic medicine · 2013Article
- Real-Time PCR detection and quantitation ofAnnals of gastroenterology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background. Though Helicobacter pylori (HP) infections have progressively declined throughout most of the industrialized countries, a gradual increase in failure of HP eradication treatments is observed. Aim. To critically review evidence on the efficacy of the therapeutic availabilities for HP eradication, as yet. Methods. A selection of Clinical Trials, Systematic Reviews and Meta-analyses within the time period 2010-2012, was performed through a Medline search. Previous references were included when basically supporting the first selection. Results. An increasing rise in HP resistance rates for antimicrobial agents is currently observed. Further causes of HP treatment failure include polymorphisms of the CYP 2C19, an increased body mass index (BMI), smoking, poor compliance and re-infections. Alternative recent approaches to standard triple therapy have been attempted to increase the eradication rate, including bismuth-containing quadruple therapy, non-bismuth containing quadruple therapy, sequential therapy and levofloxacin-containing regimens. Conclusions. The main current aims should be the maintenance of a high eradication rate (>85%) of HP and the prevention of any increase in antimicrobial resistance. In the next future, the perspective of a tailored therapy could optimize eradication regimens within the different countries.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.